{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:21:36Z","timestamp":1791084096529,"version":"4.1.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,9]],"date-time":"2021-09-09T00:00:00Z","timestamp":1631145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001279","name":"Great Ormond Street Hospital Children's Charity","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001279","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019256","name":"NIHR Great Ormond Street Hospital Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.omtm.2021.09.005","type":"journal-article","created":{"date-parts":[[2021,9,14]],"date-time":"2021-09-14T02:40:59Z","timestamp":1631587259000},"page":"135-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"special_numbering":"C","title":["Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0582-540X","authenticated-orcid":false,"given":"Julien","family":"Baruteau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6335-9104","authenticated-orcid":false,"given":"Sharon C.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berna Seker","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5450-8801","authenticated-orcid":false,"given":"Dany P.","family":"Perocheau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Eaglestone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Burke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6097-6115","authenticated-orcid":false,"given":"Adrian J.","family":"Thrasher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4970-4730","authenticated-orcid":false,"given":"Simon N.","family":"Waddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4772-8651","authenticated-orcid":false,"given":"Leszek","family":"Lisowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian E.","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9712-6122","authenticated-orcid":false,"given":"Paul","family":"Gissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.omtm.2021.09.005_bib1","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.ymgme.2010.01.014","article-title":"Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium","volume":"100","author":"Seminara","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.005_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ymgme.2013.07.008","article-title":"The incidence of urea cycle disorders","volume":"110","author":"Summar","year":"2013","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl 1","key":"10.1016\/j.omtm.2021.09.005_bib3","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/j.ymgme.2003.08.027","article-title":"The role of liver transplantation in urea cycle disorders","volume":"81","author":"Leonard","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.005_bib4","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/lt.20587","article-title":"Current role of liver transplantation for the treatment of urea cycle disorders: a review of the worldwide English literature and 13 cases at Kyoto University","volume":"11","author":"Morioka","year":"2005","journal-title":"Liver Transpl."},{"key":"10.1016\/j.omtm.2021.09.005_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.omtm.2021.09.005_bib6","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in\u00a0vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10545-017-0053-3","article-title":"Gene therapy for monogenic liver diseases: clinical successes, current challenges and future prospects","volume":"40","author":"Baruteau","year":"2017","journal-title":"J.\u00a0Inherit. Metab. Dis."},{"key":"10.1016\/j.omtm.2021.09.005_bib8","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant","volume":"377","author":"George","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.09.005_bib9","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.09.005_bib10","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2021.09.005_bib11","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","article-title":"The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL\/6J Mice","volume":"26","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib12","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/hum.2020.182","article-title":"Moving Forward After Two Deaths in a Gene Therapy Trial of Myotubular Myopathy","volume":"31","author":"Wilson","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib14","series-title":"Press Release. Ultragenyx Announces Positive Longer-term Results from First Three Cohorts of Phase 1\/2 Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency","year":"2020"},{"key":"10.1016\/j.omtm.2021.09.005_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nature12875","article-title":"Selection and evaluation of clinically relevant AAV variants in a xenograft liver model","volume":"506","author":"Lisowski","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2021.09.005_bib16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV Capsids with Combined High Human Liver Transduction In\u00a0Vivo and Unique Humoral Seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fimmu.2014.00009","article-title":"Mapping the AAV Capsid Host Antibody Response toward the Development of Second Generation Gene Delivery Vectors","volume":"5","author":"Tseng","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2021.09.005_bib18","doi-asserted-by":"crossref","first-page":"E4812","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2021.09.005_bib19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/hum.2018.098","article-title":"Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort","volume":"30","author":"Perocheau","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib20","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/blood-2018-99-115495","article-title":"A Phase 1\/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds","volume":"132","author":"High","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.005_bib21","series-title":"Press Release. LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1\/2 SUNRISE Clinical Trial for the\u00a0Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia","year":"2021"},{"key":"10.1016\/j.omtm.2021.09.005_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/mt.2016.61","article-title":"Superior In\u00a0vivo Transduction of Human Hepatocytes Using Engineered AAV3 Capsid","volume":"24","author":"Vercauteren","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.omtm.2020.11.005","article-title":"Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector","volume":"20","author":"De Sabbata","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2021.09.005_bib24","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/mt.2015.179","article-title":"Comparative Study of Liver Gene Transfer With AAV Vectors Based on Natural and Engineered AAV Capsids","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/mt.2010.274","article-title":"Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins","volume":"19","author":"Nathwani","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib26","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1089\/hum.2013.166","article-title":"Safety and liver transduction efficacy of rAAV5-cohPBGD in nonhuman primates: a potential therapy for acute intermittent porphyria","volume":"24","author":"Pa\u00f1eda","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib27","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib28","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"Calcedo","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omtm.2021.09.005_bib29","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.omtm.2021.09.005_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1089\/humc.2016.048","article-title":"AAV Natural Infection Induces Broad Cross-Neutralizing Antibody Responses to Multiple AAV Serotypes in Chimpanzees","volume":"27","author":"Calcedo","year":"2016","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.omtm.2021.09.005_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2021.09.005_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nm1549","article-title":"CD8(+) T-cell responses to adeno-associated virus capsid in humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2021.09.005_bib33","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.omtm.2021.09.005_bib34","doi-asserted-by":"crossref","first-page":"6459","DOI":"10.1182\/blood-2010-10-314518","article-title":"The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.005_bib35","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood-2002-02-0589","article-title":"Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques","volume":"100","author":"Nathwani","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2021.09.005_bib36","series-title":"Press Release. Spark Therapeutics Announces Updated Data on SPK-8011 from Phase 1\/2 Clinical Trial in Hemophilia A at ISTH 2020 Virtual Congress","year":"2020"},{"key":"10.1016\/j.omtm.2021.09.005_bib37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/1096-8628(20000814)93:4<313::AID-AJMG11>3.0.CO;2-M","article-title":"Genotype spectrum of ornithine transcarbamylase deficiency: correlation with the clinical and biochemical phenotype","volume":"93","author":"McCullough","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtm.2021.09.005_bib38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1002\/(SICI)1096-8628(19970905)71:4<378::AID-AJMG2>3.0.CO;2-Q","article-title":"The ornithine transcarbamylase (OTC) gene: mutations in 50 Japanese families with OTC deficiency","volume":"71","author":"Matsuda","year":"1997","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtm.2021.09.005_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/ajmg.1320380119","article-title":"Retrospective survey of urea cycle disorders: Part 1. Clinical and laboratory observations of thirty-two Japanese male patients with ornithine transcarbamylase deficiency","volume":"38","author":"Matsuda","year":"1991","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.omtm.2021.09.005_bib40","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jgg.2015.04.003","article-title":"Genotype-Phenotype Correlations in Ornithine Transcarbamylase Deficiency: A Mutation Update","volume":"42","author":"Caldovic","year":"2015","journal-title":"J.\u00a0Genet. Genomics"},{"key":"10.1016\/j.omtm.2021.09.005_bib41","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1126\/science.1173635","article-title":"Caloric restriction delays disease onset and mortality in rhesus monkeys","volume":"325","author":"Colman","year":"2009","journal-title":"Science"}],"container-title":["Molecular Therapy - Methods &amp; Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012100142X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S232905012100142X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:25:52Z","timestamp":1762421152000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S232905012100142X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":41,"alternative-id":["S232905012100142X"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2021.09.005","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of an engineered hepatotropic AAV gene therapy for ornithine transcarbamylase deficiency in cynomolgus monkeys","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2021.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s).","name":"copyright","label":"Copyright"}]}}